Cancer research
Researchers at the National Institutes of Health (NIH) are studying a combination of immunotherapy drugs to help the immune system fight head and neck squamous cell carcinoma (HNSCC), a type of cancer with a low five-year survival rate of less than 50%. The trial, led by Charalampos Floudas, M.D.
Cancer research
Investigators at Sundsvall Hospital have been studying the effects of communication on cancer treatment outcomes. The research aimed to explore whether therapists' positive communication could strengthen positive treatment expectations and alleviate chemotherapy-induced nausea and vomiting. The study involved 198 patients with breast, colorectal, or bladder cancer undergoing neo-/adjuvant
Cancer research
National Cancer Institute (NCI) has announced an interventional clinical trial to assess the feasibility of a survivin peptide vaccine, called SurVaxM, as an interception agent in patients at high risk for lung cancer. The trial's principal investigator is Saikrishna S Yendamuri, and it aims to enroll 80 participants
Cancer research
Researchers at the University of California, Irvine have made a significant breakthrough in rectal cancer treatment. According to a phase II trial, short-course radiation therapy (SC RT) followed by three months of trifluridine/tipiracil (FTD/TPI) plus oxaliplatin (TASOX) chemotherapy has shown promising results in treating intermediate-risk rectal cancer. The
Cancer research
A new clinical trial at Sunnybrook Health Sciences Centre aims to study the effectiveness of a combined radiation therapy approach for patients with large brain tumors. The trial, which is currently recruiting participants, will investigate the use of the Gamma Knife and a linear accelerator to deliver precise radiation therapy
Cancer
Kathy Coleman, a long-time supporter of University Hospitals, has pledged $3.5 million to the University Hospitals Seidman Cancer Center to fuel the future of clinical trials. The gift will enable the center to expand its clinical trials program, tripling patient capacity by 2030 and bringing potentially life-extending treatments to
Cancer
Ryvu Therapeutics, a clinical-stage drug discovery and development company, has entered a strategic agreement with BioNTech to support clinical trials for investigational cancer immunotherapies in Poland. The agreement aims to accelerate site activation and patient enrollment for multiple of BioNTech's priority oncology clinical programs in Poland. Ryvu will
Cancer
The oncolytic virus cancer therapy pipeline landscape is booming, with over 120 active players working to develop more than 125 pipeline therapies for the treatment of cancer. The pipeline is filled with promising oncolytic virus therapies, many of which are in the advanced stages of clinical development. These therapies aim
Cancer
Research conducted at the University of Texas MD Anderson Cancer Center has shown promising results for the treatment of follicular lymphoma using acalabrutinib, lenalidomide, and rituximab. The phase II trial involved 24 patients with previously untreated follicular lymphoma and high tumor burden, who were treated with the combination of drugs.
Diseases
Clinical trial investigators are racing to develop new treatments for Acute Myeloid Leukemia (AML), one of the most aggressive forms of blood cancer. Jacqueline Garcia, MD has recently listed an interventional clinical trial, Phase 1, 2, to Study Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase
Diseases
Research at the Oxford University Clinical Research Unit in Hanoi, Vietnam, has identified a significant correlation between Klebsiella pneumoniae with capsule type K64 and invasive disease in the community. The study, which involved isolating and analyzing 93 K. pneumoniae samples from hospitalized patients and 110 commensal isolates from healthy volunteers,
Diseases
The Lyme disease pipeline is abuzz with activity as numerous companies work tirelessly to develop effective treatment therapies. According to a recent report by DelveInsight, the Lyme disease pipeline consists of 7+ key companies, with 7+ Lyme disease treatment therapies in various stages of clinical development. The report provides an
